F2RL1 and neoplasm: On the same occasion, a recent study examined Edoxaban, one of the NOACs, and found that it significantly inhibits tumour cell proliferation via the factor Xa-PAR2 (Protease-Activated Receptor 2) pathway, which is activated by coagulation and inflammation in Colon26-inoculated mice, ultimately resulting in tumour cell apoptosis (186).